{"url_path":"/sec/sbfmw/10-q/2026/body","section_key":"body","section_title":"Body","topic":"sec","document":{"doc_type":"10-Q","doc_date":"2026-05-13","source_url":"https://www.sec.gov/Archives/edgar/data/1402328/0001683168-26-003819-index.html","accession_number":"0001683168-26-003819","cik":"0001402328","ticker":"SBFM","issuer_name":"Sunshine Biopharma Inc.","edgar_url":"https://www.sec.gov/Archives/edgar/data/1402328/0001683168-26-003819-index.html","primary_entity_key":"0001402328","primary_entity_name":"Sunshine Biopharma Inc."},"word_count":512,"has_tables":true,"body_markdown":"EX-31.1\n2\nsunshine_ex3101.htm\nCERTIFICATION\n\n**Exhibit 31.1**\n\n**CERTIFICATION\nPURSUANT TO**\n\n**18\nUSC, SECTION 1350,**\n\n**AS\nADOPTED PURSUANT TO**\n\n**SECTION\n302 OF THE SARBANES OXLEY ACT OF 2002**\n\nI,\nDr. Steve N. Slilaty, certify that:\n\n1.\nI have reviewed this quarterly\nreport on Form 10-Q of Sunshine Biopharma Inc.\n\n2.\nBased on my knowledge, this\nreport does not contain any untrue statement of a material fact or omit to state a material fact necessary in order to make the statements\nmade, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this\nreport.\n\n3.\nBased on my knowledge, the\nfinancial statements, and other financial information included in this report, fairly present in all material respects the financial\ncondition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report.\n\n4.\nThe registrant’s other\ncertifying officer(s) and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange\nAct Rules 13a-15(e) and 15d-15(e)) and internal controls over financial reporting (as defined in Exchange Act Rules 13a-15(f) and\n15d-15(f)) for the registrant and have:\n\na.\nDesigned such disclosure\ncontrols and procedures, or caused such disclosure controls and procedure to be designed under our supervision, to ensure that material\ninformation relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities,\nparticularly during the period in which this report is being prepared;\n\nb.\nDesigned such internal control\nover financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide\nreasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes\nin accordance with generally accepted accounting principles;\n\nc.\nEvaluated the effectiveness\nof the registrant's disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the\ndisclosure controls and procedures, as of the end of the period covered by this report based upon such evaluation; and\n\nd.\nDisclosed in this report\nany change in the registrant’s internal control over financial reporting that occurred during the registrant’s most recent\nfiscal quarter (the registrant’s fourth quarter in the case of an annual report) that has materially affected, or is reasonably\nlikely to materially affect, the registrant’s internal control over financial reporting; and\n\n5.\nThe registrant’s other\ncertifying officer(s) and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to\nthe registrant's auditors and the audit committee of the registrant’s board of directors (or persons performing the equivalent\nfunctions):\n\na.\nAll significant deficiencies\nand material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely\naffect the registrant's ability to record, process, summarize and report financial information; and\n\nb.\nAny fraud, whether or not\nmaterial, that involves management or other employees who have a significant role in the registrant’s internal control over\nfinancial reporting.\n\nDated: May 13,\n2026\n\n/s/\nDr. Steve N. Slilaty\n\nDr.\nSteve N. Slilaty, Chief Executive Officer\n\n** **"}